Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nautilus Biotechnology, Inc.NAUT · Entity 6679 | CFO and Treasurer | March 02, 2026 | March 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nautilus Biotechnology, Inc.
Report date March 02, 2026 · Filed March 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.32 · Expires 2036-03-02 | Direct | 160,000 |
Reported balance
After 2026-03-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-02 · Grant · Acquired 160,000 · Balance 160,000 F1: Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2026 Filed Mar 4, 2026 22:31 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | GrantStock Option (Right to Buy) · Derivative | 160,000 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001856938-26-000001 · wk-form4_1772663494.xml · derivative · entry 1 Mowry Anna · CIK 0001856938 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2036-03-02 F1 · derivative.exercise_date: Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2026. Read SEC document |
| May 29, 2025 Filed Jun 2, 2025 21:12 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | PurchaseCommon Stock | 15,000 | $0.77 | $11,488.50 |
DisclosureSEC source: 0001808805-25-000051 · wk-form4_1748898746.xml · nonDerivative · entry 1 Mowry Anna · CIK 0001856938 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,000 F1 · price: Represents the weighted average share price of an aggregate total of 15,000 shares purchased in the price range of $0.7662 to $0.7489 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes the following shares of Common Stock acquired through the Issuer's 2021 Employee Stock Purchase Plan: (i) 1,250 shares on December 1, 2022; (ii) 1,250 shares on June 1, 2023; (iii) 1,250 shares on December 1, 2023; (iv) 2,500 shares on May 31, 2024; (v) 2,500 shares on November 29, 2024; and (vi) 2,500 shares on May 30, 2025. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 21:52 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | GrantStock Option (Right to Buy) · Derivative | 160,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001808805-25-000025 · wk-form4_1741125151.xml · derivative · entry 1 Mowry Anna · CIK 0001856938 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2035-03-03 F1 · derivative.exercise_date: 25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the Vesting Commencement Date, as defined below, and the balance of the shares subject to the Option shall vest and become exercisable on a ratable, monthly basis over the 36 months succeeding such first anniversary so long as the Reporting Person remains a Service Provider as provided in the Issuer's 2021 Equity Incentive Plan. Vesting Commencement Date shall mean January 1, 2025. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:42 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | GrantStock Option (Right to Buy) · Derivative | 160,000 | $0.00 Strike: $2.72 | $0.00 |
DisclosureSEC source: 0001808805-24-000018 · wk-form4_1709674895.xml · derivative · entry 1 Mowry Anna · CIK 0001856938 · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2034-03-01 F1 · derivative.exercise_date: Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2024. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 22:19 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | GrantStock Option (Right to Buy) · Derivative | 160,000 | $0.00 Strike: $2.00 | $0.00 |
DisclosureSEC source: 0001808805-23-000031 · wf-form4_167770915010174.xml · derivative · entry 1 Mowry Anna · CIK 0001856938 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2033-02-27 F1 · derivative.exercise_date: Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2023. Read SEC document |
| August 19, 2022 Filed Aug 22, 2022 23:40 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | PurchaseCommon Stock | 17,500 | $2.30 | $40,218.50 |
DisclosureSEC source: 0001808805-22-000095 · wf-form4_166121152658656.xml · nonDerivative · entry 1 Mowry Anna · CIK 0001856938 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,750 F1 · price: Represents the weighted average share price of an aggregate total of 17,500 shares purchased in the price range of $2.29 to $2.30 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| June 27, 2022 Filed Jun 28, 2022 22:17 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | PurchaseCommon Stock | 5,500 | $2.75 | $15,124.45 |
DisclosureSEC source: 0001808805-22-000075 · wf-form4_165645463634483.xml · nonDerivative · entry 1 Mowry Anna · CIK 0001856938 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,250 F1 · balance_after: Includes 1,250 shares of Common Stock acquired on June 1, 2022 through the Issuer's 2021 Employee Stock Purchase Plan. Read SEC document |
| February 25, 2022 Filed Feb 26, 2022 01:08 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | GrantStock Option (Right to Buy) · Derivative | 280,000 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0001808805-22-000019 · wf-form4_164583765686187.xml · derivative · entry 1 Mowry Anna · CIK 0001856938 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,000 Underlying: Common Stock · 280,000 shares Expires 2032-02-25 F1 · derivative.exercise_date: Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is February 25, 2022. Read SEC document |
| November 24, 2021 Filed Nov 24, 2021 22:12 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | PurchaseCommon Stock | 15,000 | $4.58 | $68,632.50 |
DisclosureSEC source: 0001808805-21-000023 · wf-form4_163779193433755.xml · nonDerivative · entry 1 Mowry Anna · CIK 0001856938 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,500 F1 · price: Represents the weighted average share price of an aggregate total of 15,000 shares purchased in the price range of $4.545 to $4.58 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 21:12 UTC | Nautilus Biotechnology, Inc. NAUT · Entity 6679 | PurchaseCommon Stock | 17,500 | $7.71 | $134,925.00 |
DisclosureSEC source: 0001808805-21-000012 · wf-form4_162914834553171.xml · nonDerivative · entry 1 Mowry Anna · CIK 0001856938 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 F1 · price: Represents the weighted average share price of an aggregate total of 17,500 shares purchased in the price range of $7.60 to $7.73 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.